Precision Medicine in Genetic Epilepsy

Precision medicine in genetic epilepsy identifies the underlying molecular cause to guide specific treatments, avoiding ineffective or harmful therapies.

Epilepsy-related genetic conditions displaying potential specific therapeutic approaches
Figure: Genetic conditions associated with epilepsy and their targeted therapies. Shows molecular targets and specific treatments according to the affected gene.

Therapeutic Approaches by Genetic Group

  • Channelopathies (SCN1A, KCNQ2, etc.)
    • Avoid carbamazepine y phenytoin in SCN1A loss of function (risk of worsening seizures).
    • Treatments of choice: fenfluramina, cannabidiol, stiripentol, clobazam, valproate.
  • Metabolic disorders
    • SLC2A1: ketogenic diet (replaces glucose with ketone bodies).
    • ALDH7A1 y PNPO: supplementation with pyridoxine o PLP.
  • mTORopathies (TSC1/TSC2, DEPDC5)
    • Treatment: everolimus y sirolimus (mTOR inhibitors).
    • Effective in refractory epilepsy and focal cortical dysplasias.
  • Synaptic alterations (GRIN2A/B, PCDH19)
    • Memantine: for gain of function in GRIN2A/B.
    • Ganaxolone and hormonal therapies: in PCDH19.
Key Source Details

• Beltrán-Corbellini et al. (2022): Genetic identification allows reduction of iatrogenesis, better prognosis and personalized therapeutic planning.

• Moloney et al. (2022): Genetics should be integrated into presurgical evaluation. In SCN1A, surgery has worse outcomes, but should not be excluded based on genetics alone.

• Myers & Mefford (2015): Genetic epilepsy is highly heterogeneous. New genes have been identified in pathways such as mTOR, chromatin remodeling and transcriptional regulation.

Genetic identification is key to avoiding ineffective therapies and improving quality of life. Requires multidisciplinary evaluation and clinical surveillance.